lipoprotein, creatinine, C-reactive protein, and blood and erythrocyte cadmium concentrations were all objectively measured. Histories of prior coronary events were retrieved from the Swedish Hospital Discharge Register. Subjects with preexistent HF or AF were excluded. Ultimately, 4378 subjects were included in the analysis after exclusion of those with absent measured biomarkers. Cases of incident HF and AF were ascertained from the Swedish Hospital Discharge Register. Cox proportional hazards ratios (HRs) were generated in an age-adjusted model and in a model adjusted for confounders including multiple cardiovascular risk factors.
Results: New-onset HF was diagnosed in 143 subjects (53 % men), while new AF was diagnosed in 385 (52 % men). Blood cadmium concentrations (μg/L) were divided into quartiles for the purpose of analysis [median (range): Q1 0.12 (0.02-0.15); Q2 0.19 (0.15-0.24); Q3 0.31 (0.24-0.49); Q4 0.98 (0.49-5.07)]. Age-adjusted HR for new-onset HF was 2.64 (CI 1.60-4.36) when comparing the first to the fourth quartiles and remained significant in the fully adjusted model (HR 1.95; CI 1.02-3.71); however, the test for trend across quartiles was neither significant (p=0.21) nor linear. Sensitivity analysis was performed separately for each gender and only found a significant association between cadmium and new-onset HF among men. Further analysis revealed a persistently significant difference in HF between the first and fourth blood cadmium quartiles when adjustment for tobacco was performed, which remained significant when assessing blood cadmium and erythrocyte cadmium concentrations. In the multivariant adjusted model, antihypertensive use, diabetes mellitus, waist circumference, CRP, and history of a coronary event were all associated with an increased HF risk. Similarly, age, waist circumference, lipid-lowering agent use, antihypertensive use, and low serum low-density lipoprotein were associated with incident AF. No association was identified between blood cadmium concentration quartiles and AF.
Conclusion: The authors conclude that an elevated blood cadmium concentration is associated with an increased risk of HF but not AF, in this population.
Critique: The use of self-reported independent variables is a chief limitation of this study. Additionally, the nonlinear relationship between blood cadmium concentration and incident HF raises some questions regarding the conclusion, particularly whether the comparison of the first and fourth quartiles of blood cadmium concentrations is appropriate given the lack of a trend across all quartiles. Additionally, the significant association between blood cadmium concentration and incident HF was seen only in the male population when stratified by gender. Overall, the finding of a significant difference in incident HF when comparing the first and fourth quartiles of blood cadmium among males is more limited than the authors' conclusion would suggest, and is indicative of the need for further population-based investigations to better define this association.
Implication for Toxicologists: Although some data are suggestive that cadmium may be toxic to cardiac myocytes, the available epidemiologic data remain weak in the articulation of this association. This study suggests no association between blood cadmium concentrations and AF.
Zhang J, Song S, Pang Q, Zhang R, Zhou L, Liu S, Meng F, Wu Q, Liu C. Serotonin deficiency exacerbates acetaminophen-induced liver toxicity in mice. Scientific Reports 2015; 5: 8098.
Background: This article presents an animal model utilizing wild-type and serotonin-deficient mice to study the effect of serotonin in acetaminophen (APAP) hepatotoxicity. The authors propose that serotonin, well known for its neurotransmitter functions, also exerts a protective effect on liver cells in cases of APAP toxicity.
Research Question: What role does serotonin have in the liver's response to APAP toxicity in a mouse model?
Methods: Wild-type mice and mice with a knockout of TPH1, the rate-limiting enzyme in the production of peripheral serotonin, were treated with a lethal dose of APAP (600 mg/kg) and compared to a control group made up of both types of mice who instead received normal saline. Mice with sufficient serotonin, either wild-type mice or TPH1 knockout mice treated with 5-hydroxytryptophan (5-HTP; a precursor to serotonin), were compared to mice without peripheral serotonin, either serotonin knockout mice or wild-type mice treated with p-chlorophenylalanine (PCPA; an inhibitor of TPH1). Serum AST, ALT, alkaline phosphatase, and bilirubin levels were monitored, as well as glutathione and various serum cytokines. Liver samples were also collected for enzymatic activity assay and histological study.
Results: They studied a total of 15 mice in each of the 5 arms and found that the serotonin-depleted mice (TPH1 knockout or wild type receiving PCPA) were more susceptible to liver damage, with increased 5-day mortality, as compared to serotonin-rich mice (wild type or TPH1 knockout receiving 5-HTP). The groups without serotonin also depleted glutathione more rapidly. In the wild-type mice, the depletion of serotonin by PCPA exacerbated liver damage, while the addition of 5-HTP mitigated damage in the knockout mice. These results were correlated with damage seen on histological examination. Various staining techniques determined that hepatocyte proliferation was increased and apoptosis of hepatocytes was decreased in the serotonin-rich mice after APAP toxicity. Further, they found that TNF-alpha and IL-6 concentrations were decreased in the mice with sufficient serotonin after insult, suggesting decreased levels of inflammation.
Conclusion: The authors conclude that mice with sufficient serotonin exposed to APAP have lower mortality and less hepatotoxicity than serotonin-depleted mice. This effect is at least partially related to less hepatocyte apoptosis, greater hepatocyte proliferation, decreased inflammatory response, and slower glutathione depletion.
Critique: This well-designed, prospective, randomized study is limited, as with all animal studies, in its generalizability to human patients. Further, although it demonstrates a persuasive correlation between serotonin level and several outcome parameters (hepatotoxicity, mortality, levels of inflammation, and glutathione depletion) after APAP toxicity, a causal relationship should not be assumed.
Implication for Toxicologists: This study suggests a protective effect of serotonin on the hepatotoxicity seen in APAP poisoning. This correlation is compelling to the toxicologist as many of our patients are on medications or abusing drugs that modulate serotonin levels or receptor. A study to investigate the relationship between patients who have coingested a toxic dose of APAP and a serotonergic agonist or antagonist would be intriguing. Background: Although acetaminophen (APAP) remains a leading cause of overdose-related hepatotoxicity, few studies have sought to characterize APAP-related liver transplantation at a population level, or to compare the rates of APAP-related acute liver failure (ALF) across international borders. Furthermore, no previous studies have quantified the relationship between APAP-induced liver failure and the amount of APAP sold, or the number of inhabitants per year, in a given country.
Research Question: What is the relationship between APAP-related overdose and ALF leading to registration for transplantation (ALFT)? Does registration on transplantation lists following APAP overdose correlate with APAP sales or population size across seven European countries?
Methods: This was a prospective, multicenter casepopulation study undertaken between 1 January 2005 and 31
December 2007 and spanning France, Greece, Italy, Ireland, the Netherlands, Portugal, and the UK. Investigators from the Study of Acute Liver Transplantation (SALT) identified all cases of registration for liver transplant in 52 out of 57 total transplant centers in the seven countries included in the study. The documented demographic and clinical characteristics of each case were abstracted from hospital charts. Acute drug overdoses were scrutinized further for involved agent(s), case characteristics (i.e., APAP levels), and the presumed intent. Per-country population APAP exposure indices were calculated, as well as the incident cases of ALFT per capita and per ton of APAP sold.
Results: Most of 9479 subjects registered for liver transplantation had chronic liver failure, but 600 (6.3 %) cases were ALF. Of these, 301 (51.7 %) had a drug exposure etiology; 114 involved an acute overdose and 187 were exposed to some drug within 30 days of ALF onset. Of the acute overdoses, 111 (97.3 %) involved APAP and 81 additional cases had been exposed to APAP. The percentage of ALFT secondary to APAP overdose was highly variable among countries, from 52 % in Ireland to 1.0 % in Italy, and none in Greece and Portugal. Most overdose patients were female (61.3 %) and had intentional exposures (63 %). The mean age was 33.6 (SD 10.9) years and a majority (72.8 %) was transplanted. Population-based estimates ranged from 0.006 APAP-related ALFTs per million adults per year in Italy to 1.167 per million adults per year in Ireland. There was no relationship between the rate of APAP-related ALFT and the per capita sales of APAP. Non-overdose ALFT rates were very similar across countries, standing in contradistinction to rates of overdoserelated ALFTs.
Conclusion: Although most patients listed for liver transplantation have chronic liver disease, APAP accounts for the vast majority of drug overdoses that result in ALFT. The rates of APAP overdose-related ALFT vary substantially across countries included in this study. The authors found no relationship between the amount of APAP sold and rates of APAP-related ALFT across Europe, suggesting that limiting access to the drug would not necessarily decrease overdose.
Critique: The chief limitation of the study is its use of aggregate national data as a predictor of individual outcomes. Additionally, exposure data was abstracted from hospital charts and inevitably included self-reports of the history of drug use or overdose. Finally, the authors did not control for co-ingestions or the use of ethanol.
Implication for Toxicologists: Although APAP is the leading cause of ALF in developed countries, the rates of APAP overdose-related ALFT vary substantially across countries for unknown reasons. Additional research is needed to determine factors that affect a population's risk for APAPrelated liver transplant.
